Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Animal Health Sales
>
Novartis Animal Health
>
It is Merck!
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5002608"]Keep it civil people. NAH seems to suffer from a lack of decision-making from the mother ship...reluctance to invest in animal health. Merck suffers from the Intervet hang-over, short term thinking and a leadership vacuum. Merck will do anything to make their numbers and does not treat its people well. BI and Elanco will benefit and grow in this current environment because, while slow to move, their strategy seems sound...longer term thinking. Look for Elanco to buy NAH as their larger entree into vaccines. Novartis will buy Merck consumer goods outright to shed cash and become large enough to work the consumer market product lines. Given the dominance of the European vaccine group within MAH and the failures on the small molecule side look to MAH to continue to lose market share in the USA to Zoetis and Elanco, ineffectiveness in foreign markets such as China and desperate acquisitions of smaller hopefulls?[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5002608"]Keep it civil people. NAH seems to suffer from a lack of decision-making from the mother ship...reluctance to invest in animal health. Merck suffers from the Intervet hang-over, short term thinking and a leadership vacuum. Merck will do anything to make their numbers and does not treat its people well. BI and Elanco will benefit and grow in this current environment because, while slow to move, their strategy seems sound...longer term thinking. Look for Elanco to buy NAH as their larger entree into vaccines. Novartis will buy Merck consumer goods outright to shed cash and become large enough to work the consumer market product lines. Given the dominance of the European vaccine group within MAH and the failures on the small molecule side look to MAH to continue to lose market share in the USA to Zoetis and Elanco, ineffectiveness in foreign markets such as China and desperate acquisitions of smaller hopefulls?[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Animal Health Sales
>
Novartis Animal Health
>
It is Merck!
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Animal Health Sales
>
Novartis Animal Health
>
It is Merck!
>